Table 1 Characteristics of patients in the training and testing cohorts
Characteristic | Training cohort | P-value | Testing cohort | P-value | ||
|---|---|---|---|---|---|---|
LNM (+) | LNM (−) | LNM (+) | LNM (−) | |||
Sex, No. (%) | Â | Â | 0.451 | Â | Â | 0.366 |
 Male | 16 (72.73) | 37 (63.79) | 11 (64.71) | 49 (79.03) | ||
 Female | 6 (27.27) | 21 (36.21) | 6 (35.29) | 13 (20.97) | ||
Age, mean ± SD, years | 59.82 ± 11.93 | 62.52 ± 10.69 | 0.276 | 58.82 ± 8.83 | 62.60 ± 9.86 | 0.173 |
CEA, No, (%) | Â | Â | 0.114 | Â | Â | 0.204 |
 Median (IQR) | 2.19 (1.44–2.54) | 1.31 (1.02–2.44) | 2.46 (1.50–3.10) | 1.86 (1.14–2.76) | ||
 Normal | 22 (100.00) | 55 (94.83) | 17 (100.00) | 59 (95.16) | ||
 Abnormal | 0 (0.00) | 3 (5.17) | 0 (0.00) | 3 (4.84) | ||
CA19-9, No, (%) | Â | Â | 0.171 | Â | Â | 0.867 |
 Median (IQR) | 11.95 (8.22–16.46) | 8.97 (6.24–15.59) | 12.30 (7.12–16.11) | 9.99 (6.56–15.81) | ||
 Normal | 21 (95.45) | 57 (98.28) | 17 (100.00) | 60 (96.77) | ||
 Abnormal | 1 (4.55) | 1 (1.72) | 0 (0.00) | 2 (3.23) | ||
CA125, No, (%) | Â | Â | 0.035* | Â | Â | 0.308 |
 Median (IQR) | 14.18 (8.70–22.66) | 8.81 (5.43–16.04) | 10.25 (8.69–13.10) | 8.85 (4.95–15.69) | ||
 Normal | 20 (90.91) | 57 (98.28) | 16 (94.12) | 60 (96.77) | ||
 Abnormal | 2 (9.09) | 1 (1.72) | 1 (5.88) | 2 (3.23) | ||
Pathologic grade, No, (%) | Â | Â | 0.349 | Â | Â | 0.410 |
 Low grade | 12 (54.55) | 22 (37.93) | 6 (35.29) | 20 (32.26) | ||
 Median grade | 9 (40.91) | 34 (58.62) | 11 (64.71) | 36 (58.06) | ||
 High grade | 1 (4.54) | 2 (3.45) | 0 (0.00) | 6 (9.68) | ||
CT-reported LNM status, No, (%) |  |  | < 0.001* |  |  | < 0.001* |
 LNM0 | 12 (54.55) | 54 (93.10) | 11 (64.71) | 58 (93.55) | ||
 LNM1 | 10 (45.45) | 4 (6.90) | 6 (35.29) | 4 (6.45) | ||
Tumor infiltration depth, No, (%) |  |  | 0.181 |  |  | < 0.001* |
 T1a | 4 (18.18) | 20 (33.48) | 0 (0.00) | 20 (32.26) | ||
 T1b | 9 (40.91) | 25 (43.10) | 4 (23.53) | 31 (50.00) | ||
 T2 | 9 (40.91) | 13 (22.41) | 13 (76.47) | 11 (17.74) | ||